logo

BCDA

Biocardia·NASDAQ
--
--(--)
--
--(--)
2.87 / 10
Underperform

The company exhibits subpar fundamental metrics (2.9/10). Strengths observed in Inventory turnover ratio and PB, balanced by issues in PS and GPOA. Lead to constrained appraisal.

Fundamental(2.87)SentimentTechnical

Analysis Checks(5/10)

PB
Value4.37
Score2/3
Weight15.55%
1M Return12.76%
PCF
Value-2.79
Score3/3
Weight24.53%
1M Return18.17%
PS
Value1339.46
Score1/3
Weight10.33%
1M Return8.23%
Inventory turnover ratio
Value38.58
Score3/3
Weight6.86%
1M Return6.49%
PE
Value-4.45
Score0/3
Weight5.80%
1M Return5.19%
GPM
Value0.20
Score1/3
Weight8.49%
1M Return7.03%
PB-ROE
Value3.35
Score2/3
Weight14.86%
1M Return12.31%
Fixed assets turnover ratio
Value1091.49
Score3/3
Weight1.45%
1M Return1.60%
GPOA
Value0.10
Score0/3
Weight7.78%
1M Return6.60%
Asset-MV
Value-0.02
Score0/3
Weight4.35%
1M Return3.71%
Is BCDA undervalued or overvalued?
  • BCDA scores 2.87/10 on fundamentals and holds a Premium valuation at present. Backed by its -360.51% ROE, 0.00% net margin, -1.51 P/E ratio, 5.05 P/B ratio, and 64.23% earnings growth, these metrics solidify its Underperform investment rating.